GlobeNewswire Inc | Sep 6, 2020 10:59PM EDT

September 07, 2020

NEW YORK, Sept. 06, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Bayer Aktiengesellschaft (Bayer or the Company) (OTCMKTS: BAYRY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Bayer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 10, 2018, a jury in the action Johnson v. Monsanto Co., No. CGC-16-550128 (Cal. Super. Ct., Cnty. of S.F.) (the Johnson Case) found unanimously that the glyphosate-based Roundup weed killer manufactured by Bayers subsidiary Monsanto Company (Monsanto) was a substantial factor in causing the plaintiff to develop non-Hodgkins lymphoma and that Monsanto knew, or should have known, the risks associated with exposure to the chemical and failed to warn of this severe health hazard. The jury also found that Monsanto acted with malice or oppression and should be punished for its conduct. Accordingly, the jury ordered Monsanto to pay $39 million in compensatory damages and $250 million in punitive damages. On this news, the price of Bayer ADRs declined $3.00 per ADR, or 11.28%, to close at $23.59 per ADR.

Then, on October 22, 2018, although the court in the Johnson Case reduced the award of punitive damages from $250 million to $39 million to match the compensatory damages awarded to the plaintiff, the court otherwise denied Monsantos motion for judgment notwithstanding the verdict and Monsantos motion for a new trial, and upheld the jurys verdict, ruling that there is no legal basis to disturb the jurys determination that plaintiffs exposure to [glyphosate-based herbicides] was a substantial factor in causing his [non-Hodgkins lymphoma]. On this news, the price of Bayer ADRs declined $1.90 per ADR, or 8.64%, to close at $20.10 per ADR.

Finally, on March 19, 2019, a jury in the action Hardeman v. Monsanto Co., No. 3:16-cv-525 (N.D. Cal.) the first federal Roundup cancer lawsuit to proceed to trialissued a verdict on causation in phase one of the bifurcated trial, finding that plaintiffs exposure to Roundup was a substantial factor in causing his non-Hodgkins lymphoma. On this news, the price of Bayer ADRs declined $1.82 per ADR, or 9.25%, to close at $17.85 per ADR.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com